Europe Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type, By Therapy Type, By Country and Growth Forecast, 2023

List of Tables

The Europe Non Hodgkin Lymphoma Therapeutics Market would witness market growth of 8.0% CAGR during the forecast period (2023-2030).

The primary driver for adopting NHL therapeutics is their efficacy in improving patient outcomes. Novel therapies, especially immunotherapies like monoclonal antibodies and CAR-T cell therapies, have remarkably succeeded in inducing durable responses and achieving higher remission rates. The shift towards precision medicine, enabled by molecular profiling and biomarker identification, has fueled the adoption of targeted therapies. Tailoring treatment strategies based on the genetic makeup of the lymphoma and individual patient characteristics has led to more effective and personalized interventions.

Diversifying treatment options beyond traditional chemotherapy has expanded the therapeutic arsenal available to healthcare practitioners. Targeted therapies, such as BTK and PI3K inhibitors, offer alternatives for patients who may not respond well to conventional treatments. CAR-T cell therapies have been a game-changer in the treatment landscape. These cellular therapies have been adopted because they induce deep and durable responses, particularly in patients with relapsed or refractory NHL.

According to a report on the French aging policy published by the UN, as in other European countries, France faces a continuous and significant increase in the number of older people. The nation had 15 million people aged more than 60 in France in 2012, expected to reach 24 million in 2060. Therefore, all these factors will uplift the regional market's expansion in the coming years.

The Germany market dominated the Europe Non Hodgkin Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,069.2 Million by 2030. The UK market is experiencing a CAGR of 7.1% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 8.9% during (2023 - 2030).

Based on Cell Type, the market is segmented into B-Cell Lymphoma and T-Cell Lymphoma. Based on Therapy Type, the market is segmented into Radiation Therapy, Chemotherapy, Targeted Therapy, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sanofi S.A.
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Johnson & Johnson (Johnson & Johnson Services, Inc.)
Takeda Pharmaceutical Company Limited
Bayer AG
Bristol-Myers Squibb Company

Europe Non Hodgkin Lymphoma Therapeutics Market Report Segmentation

By Cell Type

B-Cell Lymphoma
T-Cell Lymphoma

By Therapy Type

Radiation Therapy
Chemotherapy
Targeted Therapy
Others

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Europe Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
- 1.4.2 Europe Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
- 1.4.3 Europe Non Hodgkin Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
3.3 Porter Five Forces Analysis

Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.

Chapter 5. Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type

5.1 Europe B-Cell Lymphoma Market by Country
5.2 Europe T-Cell Lymphoma Market by Country

Chapter 6. Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type

6.1 Europe Radiation Therapy Market by Country
6.2 Europe Chemotherapy Market by Country
6.3 Europe Targeted Therapy Market by Country
6.4 Europe Others Market by Country

Chapter 7. Europe Non Hodgkin Lymphoma Therapeutics Market by Country

7.1 Germany Non Hodgkin Lymphoma Therapeutics Market
- 7.1.1 Germany Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.1.2 Germany Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2 UK Non Hodgkin Lymphoma Therapeutics Market
- 7.2.1 UK Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.2.2 UK Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3 France Non Hodgkin Lymphoma Therapeutics Market
- 7.3.1 France Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.3.2 France Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4 Russia Non Hodgkin Lymphoma Therapeutics Market
- 7.4.1 Russia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.4.2 Russia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.5 Spain Non Hodgkin Lymphoma Therapeutics Market
- 7.5.1 Spain Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.5.2 Spain Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.6 Italy Non Hodgkin Lymphoma Therapeutics Market
- 7.6.1 Italy Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.6.2 Italy Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.7 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market
- 7.7.1 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.7.2 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type

Chapter 8. Company Profiles

8.1 Pfizer, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional & Segmental Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Product Launches and Product Expansions:
  - 8.1.5.3 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Segmental and Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
8.3 Sanofi S.A.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
- 8.3.6 SWOT Analysis
8.4 AbbVie, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Acquisition and Mergers:
- 8.4.6 SWOT Analysis
8.5 Novartis AG
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 GlaxoSmithKline PLC
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental &Regional Analysis
- 8.7.4 SWOT Analysis
8.8 Takeda Pharmaceutical Company Limited
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 SWOT Analysis
8.9 Bayer AG
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
8.10. Bristol-Myers Squibb Company
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 SWOT Analysis

LIST OF TABLES

TABLE 1 Europe Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 Europe Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 3 Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 4 Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 5 Europe B-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 6 Europe B-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 7 Europe T-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 8 Europe T-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 9 Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 10 Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 11 Europe Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Radiation Therapy Market by Country, 2023 - 2030, USD Million
TABLE 13 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 17 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 19 Europe Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Non Hodgkin Lymphoma Therapeutics Market by Country, 2023 - 2030, USD Million
TABLE 21 Germany Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 22 Germany Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 23 Germany Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 24 Germany Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 25 Germany Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 26 Germany Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 27 UK Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 28 UK Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 29 UK Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 30 UK Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 31 UK Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 32 UK Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 33 France Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 34 France Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 35 France Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 36 France Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 37 France Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 38 France Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 39 Russia Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 Russia Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 41 Russia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 42 Russia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 43 Russia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 44 Russia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 45 Spain Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 46 Spain Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 47 Spain Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 48 Spain Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 49 Spain Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 50 Spain Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 51 Italy Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 Italy Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 53 Italy Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 54 Italy Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 55 Italy Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 56 Italy Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 57 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 58 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 59 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 60 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 61 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 62 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 63 Key Information - Pfizer, Inc.
TABLE 64 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 65 Key Information - Sanofi S.A.
TABLE 66 Key information - AbbVie, Inc.
TABLE 67 Key Information - Novartis AG
TABLE 68 Key Information - GlaxoSmithKline PLC
TABLE 69 Key Information - Johnson & Johnson
TABLE 70 Key Information - Takeda Pharmaceutical Company Limited
TABLE 71 Key Information - Bayer AG
TABLE 72 Key Information - Bristol-Myers Squibb Company

Europe Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type, By Therapy Type, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents